Dopamine D-2 Agonists with High and Low Efficacies: Differentiation by Behavioural Techniques

Overview

Journal J Neural Transm Gen Sect

Specialties Neurology
Physiology

Date 1990 Jan 1

PMID 2137705

Citations 7

Authors

J Arnt

J Hyttel

Affiliations

Soon will be listed here.

Abstract

The effects of the dopamine (DA) D-2 antagonist YM 09151-2 and the DA D-2 agonists terguride, preclamol, EMD 23448, B-HT 920, quinpirole and (-)-NPA were studied in a battery of behavioural tests in order to evaluate their relative efficacies. Furthermore, their affinities for DA D-2 receptors labelled by 3H-N-0437 were measured in vitro. All agonists reduced spontaneous locomotor activity and induced marked contralateral circling behaviour in 6-hydroxy-DA-lesioned rats. Quinpirole and (-)-NPA increased motor activity after high doses. YM 09151-2 did not induce circling. In hemitransected rats quinpirole and (-)-NPA had weak effects when given alone, whereas the other agonists were ineffective. After combination with DA D-1 agonist SK&F 38393, B-HT 920 became effective, and the effects of quinpirole and (-)-NPA were facilitated. EMD 23448, preclamol and terguride were not active. In contrast, the two latter compounds fully inhibited the response to apomorphine. In stereotypy experiments a similar activity pattern was observed. Finally, drug discrimination studies showed that quinpirole, (-)-NPA and B-HT 920 substituted for the stimulus effects induced by d-amphetamine or (-)-NPA in different groups of rats. EMD 23448 induced intermediate effects, whereas preclamol and terguride had weak effects. None of the partial agonists inhibited the response of d-amphetamine. YM 09151-2 potently inhibited the effect of d-amphetamine. The results suggest that DA D-2 agonists can be ranked according to gradually increasing agonist efficacies rather than classified into autoreceptor-selective versus nonselective D-2 agonists. Implications of this hypothesis are discussed.

Citing Articles

Behavioral effects of dopamine receptor inactivation in the caudate-putamen of preweanling rats: role of the D2 receptor.

Der-Ghazarian T, Widarma C, Gutierrez A, Amodeo L, Valentine J, Humphrey D Psychopharmacology (Berl). 2013; 231(4):651-62.

PMID: 24057816 PMC: 3946740. DOI: 10.1007/s00213-013-3280-9.

Effects of dorsal striatal infusions of R(-)-propylnorapomorphine on kappa-opioid-mediated locomotor activity in the young rat: possible role of the indirect pathway.

Charntikov S, Halladay L, Herbert M, Marquez E, McDougall S Neuroscience. 2008; 155(3):603-12.

PMID: 18616989 PMC: 2629759. DOI: 10.1016/j.neuroscience.2008.06.019.

The partial dopamine D2-like receptor agonist terguride functions as an agonist in preweanling rats after a 5-day reserpine regimen.

Wacan J, Reichel C, Farley C, McDougall S Psychopharmacology (Berl). 2006; 185(1):104-11.

PMID: 16447063 DOI: 10.1007/s00213-005-0263-5.

The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.

McDougall S, Hernandez R, Reichel C, Farley C Psychopharmacology (Berl). 2005; 178(4):431-9.

PMID: 15765258 DOI: 10.1007/s00213-004-2033-1.

Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys.

Platt D, Rodefer J, Rowlett J, Spealman R Psychopharmacology (Berl). 2003; 166(3):298-305.

PMID: 12589523 DOI: 10.1007/s00213-002-1347-0.

References

Yarbrough G, Singh D, Haubrich D, Bendesky R, Martin G . Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists. Eur J Pharmacol. 1984; 99(1):73-8. DOI: 10.1016/0014-2999(84)90433-3. View

Johansen P, Clarkl D, White F . B-HT 920 stimulates postsynaptic D2 dopamine receptors in the normal rat: electrophysiological and behavioral evidence. Life Sci. 1988; 43(6):515-24. DOI: 10.1016/0024-3205(88)90153-1. View

Pichler L, Pifl C, Hornykiewicz O, KOBINGER W . The dopamine autoreceptor agonist B-HT 920 inhibits in vivo dopamine release into the cerebroventricular system of cats. Eur J Pharmacol. 1987; 135(2):239-42. DOI: 10.1016/0014-2999(87)90618-2. View

Arnt J . The discriminative stimulus properties of the D-1 agonist SK&F 38393 and the D-2 agonist (-)-NPA are mediated by separate mechanisms. Life Sci. 1988; 42(5):565-74. DOI: 10.1016/0024-3205(88)90098-7. View

Nielsen E, Jepsen S . Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs. Eur J Pharmacol. 1985; 111(2):167-76. DOI: 10.1016/0014-2999(85)90753-8. View

KEHR W . Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism. Eur J Pharmacol. 1984; 97(1-2):111-9. DOI: 10.1016/0014-2999(84)90518-1. View

Lang A . Manipulating the dopaminergic system in Parkinson's disease. Pharmacol Ther. 1987; 32(1):51-76. DOI: 10.1016/0163-7258(87)90063-5. View

Terai M, Usuda S, Kuroiwa I, Noshiro O, Maeno H . Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopaminergic receptors. Jpn J Pharmacol. 1983; 33(4):749-55. DOI: 10.1254/jjp.33.749. View

Pastor G, Fallon S, Welch J, Liebman J . Postsynaptic dopamine agonist properties of TL-99 are revealed by yohimbine co-treatment. Eur J Pharmacol. 1983; 87(4):459-64. DOI: 10.1016/0014-2999(83)90085-7. View

10.

Carlsson M, Eriksson E . The intrinsic activity of (-)-3-PPP (preclamol) on pituitary DA receptors in female rats is enhanced following chronic DA depletion. Life Sci. 1988; 42(5):585-8. DOI: 10.1016/0024-3205(88)90100-2. View

11.

ANDEN N, Thornstrom U . Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively. Naunyn Schmiedebergs Arch Pharmacol. 1982; 321(2):100-4. DOI: 10.1007/BF00518475. View

12.

Clark D, Hjorth S, Carlsson A . Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm. 1985; 62(1-2):1-52. DOI: 10.1007/BF01260414. View

13.

ANDEN N, Grabowska-Anden M . Increased motor activity following combined stimulation of B-HT 920-sensitive and D-1 dopamine receptors. Acta Physiol Scand. 1987; 131(1):157-8. DOI: 10.1111/j.1748-1716.1987.tb08218.x. View

14.

Arnt J, Perregaard J . Synergistic interaction between dopamine D-1 and D-2 receptor agonists: circling behaviour of rats with hemitransection. Eur J Pharmacol. 1987; 143(1):45-53. DOI: 10.1016/0014-2999(87)90733-3. View

15.

van der Weide J, DE VRIES J, Tepper P, Horn A . In vitro binding of the very potent and selective D-2 dopamine agonist, [3H]N-0437 to calf caudate membranes. Eur J Pharmacol. 1987; 134(2):211-9. DOI: 10.1016/0014-2999(87)90167-1. View

16.

Clark D, White F . D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse. 1987; 1(4):347-88. DOI: 10.1002/syn.890010408. View

17.

Hjorth S, Carlsson A, Wikstrom H, Lindberg P, Sanchez D, Hacksell U . 3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci. 1981; 28(11):1225-38. DOI: 10.1016/0024-3205(81)90448-3. View

18.

Seyfried C, Fuxe K, Wolf H, Agnati L . Demonstration of a new type of dopamine receptor agonist: an indolyl-3-butylamine. Actions at intact versus supersensitive dopamine receptors in the rat forebrain. Acta Physiol Scand. 1982; 116(4):465-8. DOI: 10.1111/j.1748-1716.1982.tb07168.x. View

19.

Clark D, Hjorth S, Carlsson A . Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm. 1985; 62(3-4):171-207. DOI: 10.1007/BF01252236. View

20.

Cunningham K, Callahan P, Appel J . Discriminative stimulus properties of lisuride revisited: involvement of dopamine D2 receptors. J Pharmacol Exp Ther. 1987; 241(1):147-51. View